15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering OKYO Pharma Ltd ADR, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $5.00 to $7.00, a moderate spread. The average target of $5.67 sits 248% above the current $1.63. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $-0.66 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to OKYO Pharma Ltd ADR.
As of Jul, 3 of 3 firms rate OKYO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
OKYO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.04 – $-0.04 · 1 analysts
Next period, 1 analysts expect OKYO Pharma Ltd ADR to earn $-0.04 a share (range $-0.04 – $-0.04), versus — a year earlier. Full-year consensus is $-0.12, growing to $-0.66 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $11.0M next year.
Top analysts covering OKYO Pharma Ltd ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OKYO.
#1
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$5.00+206.7% to target
Overall win rate
34%
+ Follow
#2
Biren Amin
Piper Sandler
Buy
$7.00+329.4% to target
Coverage
—
+ Follow
#3
WW
William Woods
B. Riley Securities
Buy
$5.00+206.7% to target
Coverage
—
+ Follow
#4
WW
William Wood
B. Riley Securities
Buy
$5.00+206.7% to target
Coverage
—
+ Follow
#5
Elemer Piros
Lucid Capital
Buy
$13.00+697.5% to target
Coverage
—
+ Follow
OKYO stock forecast FAQ
What is OKYO's average 12-month price target?+
The 3 analysts with a live target average $5.67 for OKYO Pharma Ltd ADR over the next 12 months, ranging from a $7.00 high to a $5.00 low.
Is OKYO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for OKYO?+
The Street-high target is $7.00 (Piper Sandler), and the Street-low is $5.00 (HC Wainwright & Co.). The average of all 3 active targets is $5.67.
How many Wall Street analysts cover OKYO?+
3 analysts have an active rating on OKYO Pharma Ltd ADR, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering OKYO?+
Among analysts who currently cover OKYO, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #238). Their current call is Buy with a $5.00 target.
What is OKYO Pharma Ltd ADR's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.04 – $-0.04) across 1 analysts. Full-year EPS is projected at $-0.12, rising to $-0.66 the following year.
How much revenue is OKYO Pharma Ltd ADR expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $11.0M next year.
Have analysts been upgrading or downgrading OKYO lately?+
As of Jul, 3 of 3 firms rate OKYO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OKYO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
